## Richard H Guy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8726048/publications.pdf Version: 2024-02-01



RICHARD H CUV

#	Article	IF	CITATIONS
1	Assessment of dermal bioavailability: predicting the input function for topical glucocorticoids using stratum corneum sampling. Drug Delivery and Translational Research, 2022, 12, 851-861.	5.8	3
2	Skin pharmacokinetics of diclofenac and co-delivered functional excipients. International Journal of Pharmaceutics, 2022, 614, 121469.	5.2	7
3	Reverse Iontophoretic Extraction of Skin Cancer-Related Biomarkers. Pharmaceutics, 2022, 14, 79.	4.5	5
4	Predicting topical drug clearance from the skin. Drug Delivery and Translational Research, 2021, 11, 729-740.	5.8	13
5	Skin Pharmacokinetics of Transdermal Scopolamine: Measurements and Modeling. Molecular Pharmaceutics, 2021, 18, 2714-2723.	4.6	8
6	Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model. British Journal of Clinical Pharmacology, 2020, 86, 2530-2534.	2.4	11
7	The European Medicines Agency's goals for regulatory science to 2025. Nature Reviews Drug Discovery, 2019, 18, 403-404.	46.4	17
8	Scanning the horizon: a systematic literature review of methodologies. BMJ Open, 2019, 9, e026764.	1.9	43
9	Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis. Molecular Pharmaceutics, 2019, 16, 2808-2816.	4.6	14
10	Mechanism of human nail poration by high-repetition-rate, femtosecond laser ablation. Drug Delivery and Translational Research, 2019, 9, 956-967.	5.8	5
11	Potential of iontophoresis as a drug delivery method for midazolam in pediatrics. European Journal of Pharmaceutical Sciences, 2019, 128, 137-143.	4.0	7
12	Topical bio(in)equivalence of metronidazole formulations in vivo. International Journal of Pharmaceutics, 2018, 541, 167-172.	5.2	14
13	Non-invasive, transdermal, path-selective and specific glucose monitoring via a graphene-based platform. Nature Nanotechnology, 2018, 13, 504-511.	31.5	242
14	Dermal Absorption of Pesticide Residues. Chemical Research in Toxicology, 2018, 31, 1356-1363.	3.3	8
15	Reverse Iontophoretic Extraction of Metabolites from Living Plants and their Identification by Ionâ€chromatography Coupled to High Resolution Mass Spectrometry. Phytochemical Analysis, 2017, 28, 195-201.	2.4	12
16	Bioequivalence Methodologies for Topical Drug Products: In Vitro and Ex Vivo Studies with a Corticosteroid and an Anti-Fungal Drug. Pharmaceutical Research, 2017, 34, 730-737.	3.5	24
17	Topical bioavailability of diclofenac from locally-acting, dermatological formulations. International Journal of Pharmaceutics, 2017, 529, 55-64.	5.2	38
18	Precise laser poration to control drug delivery into and through human nail. Journal of Controlled Release, 2017, 268, 72-77.	9.9	17

#	Article	IF	CITATIONS
19	Modelling drug flux through microporated skin. Journal of Controlled Release, 2016, 241, 194-199.	9.9	13
20	Femtosecond pulsed laser ablation to enhance drug delivery across the skin. Journal of Biophotonics, 2016, 9, 144-154.	2.3	21
21	Ibuprofen delivery into and through the skin from novel oxidized cellulose-based gels and conventional topical formulations. International Journal of Pharmaceutics, 2016, 514, 238-243.	5.2	29
22	Choice of Moisturiser for Eczema Treatment (COMET): feasibility study of a randomised controlled parallel group trial in children recruited from primary care. BMJ Open, 2016, 6, e012021.	1.9	20
23	Managing diabetes through the skin. Nature Nanotechnology, 2016, 11, 493-494.	31.5	26
24	Assessing the safety of cosmetic chemicals: Consideration of a flux decision tree to predict dermally delivered systemic dose for comparison with oral TTC (Threshold of Toxicological Concern). Regulatory Toxicology and Pharmacology, 2016, 76, 174-186.	2.7	50
25	The potential of polymeric film-forming systems as sustained delivery platforms for topical drugs. Expert Opinion on Drug Delivery, 2016, 13, 349-360.	5.0	44
26	Choice of Moisturiser for Eczema Treatment (COMET): study protocol for a randomized controlled trial. Trials, 2015, 16, 304.	1.6	17
27	Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds. International Journal of Pharmaceutics, 2015, 490, 404-411.	5.2	29
28	Characterisation of Skin Barrier Function Using Bioengineering and Biophysical Techniques. Pharmaceutical Research, 2015, 32, 445-457.	3.5	10
29	Iontophoretic Transdermal Sampling of Iohexol as a Non-Invasive Tool to Assess Glomerular Filtration Rate. Pharmaceutical Research, 2015, 32, 590-603.	3.5	7
30	In Vitro Method to Quantify Dermal Absorption of Pesticide Residues. Chemical Research in Toxicology, 2015, 28, 166-168.	3.3	7
31	Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 91, 9-15.	4.3	70
32	Characterization of Topical Film-Forming Systems Using Atomic Force Microscopy and Raman Microspectroscopy. Molecular Pharmaceutics, 2015, 12, 751-757.	4.6	27
33	Iontophoresis of minoxidil sulphate loaded microparticles, a strategy for follicular drug targeting?. Colloids and Surfaces B: Biointerfaces, 2015, 134, 408-412.	5.0	27
34	Molecular diffusion in the human nail measured by stimulated Raman scattering microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7725-7730.	7.1	40
35	Biophysical elucidation of the mechanism of enhanced drug release and topical delivery from polymeric film-forming systems. Journal of Controlled Release, 2015, 212, 103-112.	9.9	24
36	Drug delivery into microneedle-porated nails from nanoparticle reservoirs. Journal of Controlled Release, 2015, 220, 98-106.	9.9	38

#	Article	IF	CITATIONS
37	Topical formulation and dermal delivery of active phenolic compounds in the Thai medicinal plant – Clerodendrum petasites S. Moore. International Journal of Pharmaceutics, 2015, 478, 39-45.	5.2	12
38	A nonâ€rewarding, nonâ€aversive buprenorphine/naltrexone combination attenuates drugâ€primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm. Addiction Biology, 2014, 19, 575-586.	2.6	37
39	Characterisation of polyphenolic compounds in Clerodendrum petasites S. Moore and their potential for topical delivery through the skin. Journal of Ethnopharmacology, 2014, 154, 400-407.	4.1	34
40	Effective use of transdermal drug delivery in children. Advanced Drug Delivery Reviews, 2014, 73, 63-82.	13.7	77
41	Serious photocontact dermatitis induced by topical ketoprofen depends on the formulation. European Journal of Dermatology, 2014, 24, 365-371.	0.6	16
42	Evaluation of drug delivery to intact and porated skin by coherent Raman scattering and fluorescence microscopies. Journal of Controlled Release, 2014, 174, 37-42.	9.9	70
43	Transdermal drug delivery: 30 + years of war and still fighting!. Journal of Controlled Release, 2014, 190, 150-156.	9.9	225
44	Imaging Drug Delivery to Skin with Coherent Raman Scattering Microscopy. , 2014, , 225-231.		1
45	Effects of Iontophoresis, Hydration, and Permeation Enhancers on Human Nail Plate: Infrared and Impedance Spectroscopy Assessment. Pharmaceutical Research, 2013, 30, 1652-1662.	3.5	16
46	Skin - â€~That Unfakeable Young Surface'. Skin Pharmacology and Physiology, 2013, 26, 181-189.	2.5	4
47	Transdermal flux predictions for selected selective oestrogen receptor modulators (SERMs): Comparison with experimental results. Journal of Controlled Release, 2013, 172, 601-606.	9.9	8
48	Mechanical Tomography of Human Corneocytes with a Nanoneedle. Journal of Investigative Dermatology, 2013, 133, 1565-1571.	0.7	28
49	Products in "Bounty bags" potentially harm newborn skin. BMJ, The, 2013, 346, f3895-f3895.	6.0	0
50	Iontophoresis-Targeted, Follicular Delivery of Minoxidil Sulfate for the Treatment of Alopecia. Journal of Pharmaceutical Sciences, 2013, 102, 1488-1494.	3.3	36
51	Novel Imaging Method to Quantify Stratum Corneum in Dermatopharmacokinetic Studies. Pharmaceutical Research, 2012, 29, 2389-2397.	3.5	12
52	Novel Imaging Method to Quantify Stratum Corneum in Dermatopharmacokinetic Studies: Proof-of-Concept with Acyclovir Formulations. Pharmaceutical Research, 2012, 29, 3362-3372.	3.5	13
53	Passive and iontophoretic transdermal delivery of phenobarbital: Implications in paediatric therapy. International Journal of Pharmaceutics, 2012, 435, 76-82.	5.2	17
54	Transdermal iontophoresis of ranitidine: An opportunity in paediatric drug therapy. International Journal of Pharmaceutics, 2012, 435, 27-32.	5.2	39

#	Article	IF	CITATIONS
55	Comparison of gravimetric and spectroscopic approaches to quantify stratum corneum removed by tape-stripping. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 171-174.	4.3	38
56	Objective assessment of nanoparticle disposition in mammalian skin after topical exposure. Journal of Controlled Release, 2012, 162, 201-207.	9.9	150
57	Perturbation of solute transport at a liquid–liquid interface by polyethylene glycol (PEG): implications for PEG-induced biomembrane fusion. Physical Chemistry Chemical Physics, 2011, 13, 5346.	2.8	5
58	Assessment of Dermal Exposure to Pesticide Residues during Re-entry. Environmental Science & Technology, 2011, 45, 4609-4615.	10.0	26
59	Imaging Drug Delivery to Skin with Stimulated Raman Scattering Microscopy. Molecular Pharmaceutics, 2011, 8, 969-975.	4.6	162
60	Iontophoresis—Recent Developments. Journal of Pharmacy and Pharmacology, 2011, 50, 371-374.	2.4	55
61	Diffusion coefficient determination using a filter-paper diaphragm cell technique. Journal of Pharmacy and Pharmacology, 2011, 33, 121-123.	2.4	18
62	Mathematical models of skin permeability: An overview. International Journal of Pharmaceutics, 2011, 418, 115-129.	5.2	294
63	Optimisation of Cosolvent Concentration for Topical Drug Delivery III – Influence of Lipophilic Vehicles on Ibuprofen Permeation. Skin Pharmacology and Physiology, 2011, 24, 22-26.	2.5	28
64	Release of non-electrolytes from liposomes. Journal of Pharmacy and Pharmacology, 2011, 35, 12-14.	2.4	4
65	Trans-scleral iontophoretic delivery of low molecular weight therapeutics. Journal of Controlled Release, 2010, 147, 225-231.	9.9	54
66	Microemulsion formulations for the transdermal delivery of testosterone. European Journal of Pharmaceutical Sciences, 2010, 40, 188-196.	4.0	144
67	Extraction and quantification of amino acids in human stratum corneum <i>in vivo</i> . British Journal of Dermatology, 2010, 163, 458-465.	1.5	31
68	Effect of Aqueous Cream BP on human stratum corneum <i>inÂvivo</i> . British Journal of Dermatology, 2010, 163, 954-958.	1.5	70
69	Disposition of Charged Nanoparticles after Their Topical Application to the Skin. Skin Pharmacology and Physiology, 2010, 23, 117-123.	2.5	80
70	Uptake of Microemulsion Components into the Stratum Corneum and Their Molecular Effects on Skin Barrier Function. Molecular Pharmaceutics, 2010, 7, 1266-1273.	4.6	86
71	Non-invasive assessment of the effects of iontophoresis on human skin in-vivo. Journal of Pharmacy and Pharmacology, 2010, 53, 769-777.	2.4	55
72	Transdermal Drug Delivery. Handbook of Experimental Pharmacology, 2010, , 399-410.	1.8	65

#	Article	IF	CITATIONS
73	Predicting the Rate and Extent of Fragrance Chemical Absorption into and through the Skin. Chemical Research in Toxicology, 2010, 23, 864-870.	3.3	27
74	Measurement and prediction of the rate and extent of drug delivery into and through the skin. Expert Opinion on Drug Delivery, 2009, 6, 355-369.	5.0	40
75	Effects of Various Vehicles on Skin Hydration in vivo. Skin Pharmacology and Physiology, 2009, 22, 128-130.	2.5	21
76	Leichtnam M-L, Rolland H, Wüthrich P, Guy R. 2006. Formulation and evaluation of a testosterone transdermal spray. J Pharm Sci 95: 1693–1702 Journal of Pharmaceutical Sciences, 2009, 98, 3876.	3.3	0
77	Improved Bioequivalence Assessment of Topical Dermatological Drug Products Using Dermatopharmacokinetics. Pharmaceutical Research, 2009, 26, 316-328.	3.5	82
78	Dermatopharmacokinetics: Factors Influencing Drug Clearance from the Stratum Corneum. Pharmaceutical Research, 2009, 26, 865-871.	3.5	29
79	Drug Delivery to the Skin From Sub-micron Polymeric Particle Formulations: Influence of Particle Size and Polymer Hydrophobicity. Pharmaceutical Research, 2009, 26, 1995-2001.	3.5	35
80	Reverse Iontophoresis of Amino Acids: Identification and Separation of Stratum Corneum and Subdermal Sources In Vitro. Pharmaceutical Research, 2009, 26, 2630-2638.	3.5	18
81	Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability. British Journal of Dermatology, 2009, 160, 676-686.	1.5	37
82	Prediction of chemical absorption into and through the skin from cosmetic and dermatological formulations. British Journal of Dermatology, 2009, 160, 80-91.	1.5	44
83	Epidermal Barrier Dysfunction in Atopic Dermatitis. Journal of Investigative Dermatology, 2009, 129, 1892-1908.	0.7	612
84	Dermatopharmacokinetics of betamethasone 17-valerate: Influence of formulation viscosity and skin surface cleaning procedure. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 362-366.	4.3	35
85	Dye diffusion from microcapsules with different shell thickness into mammalian skin. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 62-68.	4.3	31
86	Extraction of amino acids by reverse iontophoresis in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 226-231.	4.3	33
87	Influence of polymer adjuvants on the ultrasound-mediated transfection of cells in culture. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 567-573.	4.3	7
88	Disposition of Nanoparticles and an Associated Lipophilic Permeant following Topical Application to the Skin. Molecular Pharmaceutics, 2009, 6, 1441-1448.	4.6	81
89	Preparation and in Vitro Evaluation of Topical Formulations Based on Polystyrene-poly-2-hydroxyl Methacrylate Nanoparticles. Molecular Pharmaceutics, 2009, 6, 1449-1456.	4.6	24
90	Influence of Ethanol on the Solubility, Ionization and Permeation Characteristics of Ibuprofen in Silicone and Human Skin. Skin Pharmacology and Physiology, 2009, 22, 15-21.	2.5	82

#	Article	IF	CITATIONS
91	Optimisation of Cosolvent Concentration for Topical Drug Delivery – II: Influence of Propylene Glycol on Ibuprofen Permeation. Skin Pharmacology and Physiology, 2009, 22, 225-230.	2.5	55
92	Novel Beads Made of Alpha-cyclodextrin and Oil for Topical Delivery of a Lipophilic Drug. Pharmaceutical Research, 2008, 25, 435-440.	3.5	37
93	In Vivo Methods for the Assessment of Topical Drug Bioavailability. Pharmaceutical Research, 2008, 25, 87-103.	3.5	214
94	Optimizing Metrics for the Assessment of Bioequivalence Between Topical Drug Products. Pharmaceutical Research, 2008, 25, 1621-1630.	3.5	41
95	Effect of propylene glycol on ibuprofen absorption into human skin in vivo. Journal of Pharmaceutical Sciences, 2008, 97, 185-197.	3.3	73
96	Iontophoresis of dexamethasone phosphate: Competition with chloride ions. Journal of Controlled Release, 2008, 131, 41-46.	9.9	21
97	Bioavailability and bioequivalence of topical glucocorticoids. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 453-466.	4.3	121
98	In vivo infrared spectroscopy studies of alkanol effects on human skin. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 1171-1175.	4.3	53
99	Non-invasive diagnosis and monitoring of chronic kidney disease by reverse iontophoresis of urea in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 1077-1082.	4.3	28
100	Extraction of amino acids by reverse iontophoresis: Simulation of therapeutic monitoring in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 908-913.	4.3	12
101	In Vitro Optimization of Dexamethasone Phosphate Delivery by Iontophoresis. Physical Therapy, 2008, 88, 1177-1185.	2.4	30
102	Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. Food and Chemical Toxicology, 2007, 45, 2533-2562.	3.6	1,336
103	Ultrasound-Mediated Gene Delivery:Â Influence of Contrast Agent on Transfection. Bioconjugate Chemistry, 2007, 18, 652-662.	3.6	70
104	Transdermal science and technology-an update. Drug Delivery System, 2007, 22, 442-449.	0.0	11
105	Impact of Antinucleants on Transdermal Delivery ofTestosterone from a Spray. Journal of Pharmaceutical Sciences, 2007, 96, 84-92.	3.3	18
106	Reverse iontophoresis of L″actate: In vitro and in vivo studies. Journal of Pharmaceutical Sciences, 2007, 96, 3457-3465.	3.3	25
107	Ibuprofen Transport into and through Skin from Topical Formulations: In Vitro–In Vivo Comparison. Journal of Investigative Dermatology, 2007, 127, 135-142.	0.7	82
108	Dermatopharmacokinetic Prediction of Topical Drug Bioavailability In Vivo. Journal of Investigative Dermatology, 2007, 127, 887-894.	0.7	74

#	Article	IF	CITATIONS
109	Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl. Journal of Controlled Release, 2007, 122, 135-140.	9.9	88
110	Quantitative structure–permeation relationship for iontophoretic transport across the skin. Journal of Controlled Release, 2007, 122, 165-172.	9.9	50
111	Enhanced Delivery of 5-Aminolevulinic Acid Esters by Iontophoresis In Vitro¶. Photochemistry and Photobiology, 2007, 77, 304-308.	2.5	3
112	Monitoring of Urea and Potassium by Reverse Iontophoresis In Vitro. Pharmaceutical Research, 2007, 24, 1131-1137.	3.5	28
113	Assessment of the "Skin Reservoir―of Urea by Confocal Raman Microspectroscopy and Reverse Iontophoresis in vivo. Pharmaceutical Research, 2007, 24, 1897-1901.	3.5	35
114	Transport Numbers in Transdermal Iontophoresis. Biophysical Journal, 2006, 90, 2822-2830.	0.5	48
115	Testosterone Hormone Replacement Therapy: State-of-the-Art and Emerging Technologies. Pharmaceutical Research, 2006, 23, 1117-1132.	3.5	16
116	Pig Ear Skin ex Vivo as a Model for in Vivo Dermatopharmacokinetic Studies in Man. Pharmaceutical Research, 2006, 23, 1850-1856.	3.5	160
117	Topical Iontophoresis of Valaciclovir Hydrochloride Improves Cutaneous Aciclovir Delivery. Pharmaceutical Research, 2006, 23, 1842-1849.	3.5	26
118	Structure–permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. European Journal of Pharmaceutical Sciences, 2006, 29, 53-59.	4.0	26
119	Prediction of iontophoretic transport across the skin. Journal of Controlled Release, 2006, 111, 362-367.	9.9	32
120	Identification of penetration enhancers for testosterone transdermal delivery from spray formulations. Journal of Controlled Release, 2006, 113, 57-62.	9.9	28
121	Electromigration of ions across the skin: Determination and prediction of transport numbers. Journal of Pharmaceutical Sciences, 2006, 95, 561-569.	3.3	21
122	Formulation and evaluation of a testosterone transdermal spray. Journal of Pharmaceutical Sciences, 2006, 95, 1693-1702.	3.3	28
123	Enhancement of Transdermal Testosterone Delivery By Supersaturation. Journal of Pharmaceutical Sciences, 2006, 95, 2373-2379.	3.3	18
124	Physical methods for gene transfer: Improving the kinetics of gene delivery into cells. Advanced Drug Delivery Reviews, 2005, 57, 733-753.	13.7	342
125	Effect of amino acid sequence on transdermal iontophoretic peptide delivery. European Journal of Pharmaceutical Sciences, 2005, 26, 429-437.	4.0	22
126	Comparison of the lipid composition of porcine buccal and esophageal permeability barriers. Archives of Oral Biology, 2005, 50, 981-987.	1.8	76

#	Article	IF	CITATIONS
127	Plasma membrane poration induced by ultrasound exposure: Implication for drug delivery. Journal of Controlled Release, 2005, 104, 213-222.	9.9	314
128	Ultrasound-mediated gene delivery: Kinetics of plasmid internalization and gene expression. Journal of Controlled Release, 2005, 104, 203-211.	9.9	90
129	Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. Journal of Controlled Release, 2005, 108, 319-330.	9.9	46
130	Evaluation of pig esophageal mucosa as a permeability barrier model for buccal tissue. Journal of Pharmaceutical Sciences, 2005, 94, 2777-2788.	3.3	88
131	Transdermal Iontophoretic Delivery of Triptorelin in Vitro. Journal of Pharmaceutical Sciences, 2005, 94, 2175-2182.	3.3	27
132	Capillary zone electrophoresis for the estimation of transdermal iontophoretic mobility. Journal of Pharmaceutical Sciences, 2005, 94, 2667-2675.	3.3	18
133	Transdermal Iontophoretic Delivery of Vapreotide Acetate AcrossPorcine Skin in Vitro. Pharmaceutical Research, 2005, 22, 1305-1312.	3.5	27
134	Transport of Fentanyl Through Pig Buccal and Esophageal Epithelia in Vitro. Influence of Concentration and Vehicle pH. Pharmaceutical Research, 2005, 22, 1525-1529.	3.5	30
135	Effect of Charge and Molecular Weight on Transdermal Peptide Delivery by Iontophoresis. Pharmaceutical Research, 2005, 22, 2069-2078.	3.5	47
136	Percutaneous Absorption of 4-Cyanophenol from Freshly Contaminated Soil in Vitro:Â Effects of Soil Loading and Contamination Concentration. Environmental Science & Technology, 2005, 39, 3723-3731.	10.0	10
137	Reverse iontophoresis of lithium: electrode formulation using a thermoreversible polymer. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 237-240.	4.3	9
138	Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opinion on Drug Delivery, 2005, 2, 533-548.	5.0	98
139	Noninvasive and Minimally Invasive Methods for Transdermal Glucose Monitoring. Diabetes Technology and Therapeutics, 2005, 7, 174-197.	4.4	90
140	Modeling Dermal Absorption from Soils and Powders Using Stratum Corneum Tape-Stripping In Vivo. , 2005, , 191-212.		1
141	lontophoresis. , 2005, , 177-219.		5
142	Reverse iontophoresis for non-invasive transdermal monitoring. Physiological Measurement, 2004, 25, R35-R50.	2.1	117
143	Noninvasive Glucose Monitoring by Reverse lontophoresis in Vivo: Application of the Internal Standard Concept. Clinical Chemistry, 2004, 50, 1383-1390.	3.2	100
144	Skin penetration and distribution of polymeric nanoparticles. Journal of Controlled Release, 2004, 99, 53-62.	9.9	511

#	Article	IF	CITATIONS
145	Transdermal delivery from a lipid sponge phase—iontophoretic and passive transport in vitro of 5-aminolevulinic acid and its methyl ester. Journal of Controlled Release, 2004, 100, 191-198.	9.9	58
146	Non-invasive monitoring of phenytoin by reverse iontophoresis. European Journal of Pharmaceutical Sciences, 2004, 22, 427-433.	4.0	40
147	Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Advanced Drug Delivery Reviews, 2004, 56, 77-94.	13.7	194
148	Iontophoretic drug delivery. Advanced Drug Delivery Reviews, 2004, 56, 619-658.	13.7	684
149	Quantitative Structure-Permeation Relationships (QSPeRs) to Predict Skin Permeation: A Critical Evaluation. Pharmaceutical Research, 2004, 21, 83-92.	3.5	134
150	Reverse lontophoresis as a Noninvasive Tool for Lithium Monitoring and Pharmacokinetic Profiling. Pharmaceutical Research, 2004, 21, 1214-1222.	3.5	30
151	Porcine Ear Skin as a Model for the Assessment of Transdermal Drug Delivery to Premature Neonates. Pharmaceutical Research, 2004, 21, 1390-1397.	3.5	67
152	Simultaneous Extraction of Urea and Glucose by Reverse Iontophoresis in Vivo. Pharmaceutical Research, 2004, 21, 1805-1810.	3.5	25
153	Enhancement of Topical Delivery from Biodegradable Nanoparticles. Pharmaceutical Research, 2004, 21, 1818-1825.	3.5	212
154	Development of an in vitro model for premature neonatal skin: Biophysical characterization using transepidermal water loss. Journal of Pharmaceutical Sciences, 2004, 93, 2936-2940.	3.3	26
155	Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo. International Journal of Pharmaceutics, 2004, 271, 251-256.	5.2	58
156	Lithium Monitoring by Reverse Iontophoresis in Vivo. Clinical Chemistry, 2004, 50, 2091-2100.	3.2	64
157	Electroosmosis in Transdermal Iontophoresis: Implications for Noninvasive and Calibration-Free Glucose Monitoring. Biophysical Journal, 2004, 87, 3344-3350.	0.5	74
158	Visualization of skin penetration using confocal laser scanning microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58, 301-316.	4.3	228
159	Transdermal reverse iontophoresis of valproate: a noninvasive method for therapeutic drug monitoring. Pharmaceutical Research, 2003, 20, 1508-1513.	3.5	43
160	Optimization of aminolevulinic acid delivery by iontophoresis. Journal of Controlled Release, 2003, 88, 65-70.	9.9	64
161	Frequency and thermal effects on the enhancement of transdermal transport by sonophoresis. Journal of Controlled Release, 2003, 88, 85-94.	9.9	90
162	Ultrasoundâ€Enhanced Transdermal Transport. Journal of Pharmaceutical Sciences, 2003, 92, 1125-1137.	3.3	61

#	Article	IF	CITATIONS
163	Skin Permeability Enhancement by Low Frequency Sonophoresis: Lipid Extraction and Transport Pathways. Journal of Pharmaceutical Sciences, 2003, 92, 1138-1146.	3.3	73
164	Reverse lontophoresis for Noninvasive Glucose Monitoring: The Internal Standard Concept. Journal of Pharmaceutical Sciences, 2003, 92, 2295-2302.	3.3	37
165	Enhanced Delivery of 5-Aminolevulinic Acid Esters by Iontophoresis In Vitro¶. Photochemistry and Photobiology, 2003, 77, 304.	2.5	54
166	Post-iontophoresis recovery of human skin impedance in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 53, 15-21.	4.3	31
167	In vivo assessment of skin electroporation using square wave pulses. Journal of Controlled Release, 2002, 79, 219-227.	9.9	60
168	Reverse iontophoretic monitoring in premature neonates: feasibility and potential. Journal of Controlled Release, 2002, 81, 83-89.	9.9	41
169	Biophysical Study of Porcine Ear Skin In Vitro and Its Comparison to Human Skin In Vivo. Journal of Pharmaceutical Sciences, 2002, 91, 2376-2381.	3.3	158
170	Permeation of a myristoylated dipeptide across the buccal mucosa: topological distribution and evaluation of tissue integrity. International Journal of Pharmaceutics, 2002, 231, 1-9.	5.2	31
171	Determining dermal absorption parameters in vivo from tape strip data. Pharmaceutical Research, 2002, 19, 292-298.	3.5	77
172	Quantitative structure-permeation relationships for solute transport across silicone membranes. Pharmaceutical Research, 2002, 19, 1622-1629.	3.5	55
173	Iontophoresis. , 2002, , .		0
174	Feasibility Assessment in Topical and Transdermal Delivery. , 2002, , .		0
175	Characterization of molecular transport across human stratum corneum in vivo. Cutaneous and Ocular Toxicology, 2001, 20, 279-301.	0.3	1
176	The development of skin barrier function in the neonate. Cutaneous and Ocular Toxicology, 2001, 20, 335-367.	0.3	3
177	Passive skin penetration enhancement and its quantification in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2001, 52, 103-112.	4.3	458
178	PERCUTANEOUS PENETRATION ENHANCEMENT: PHYSICOCHEMICAL CONSIDERATIONS AND IMPLICATIONS FOR PRODRUG DESIGN*. Clinical Research and Regulatory Affairs, 2001, 18, 219-233.	2.1	3
179	Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. International Journal of Pharmaceutics, 2001, 219, 11-19.	5.2	96
180	Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery. International Journal of Pharmaceutics, 2001, 224, 169-176.	5.2	44

#	Article	IF	CITATIONS
181	Permeation enhancement of a highly lipophilic drug using supersaturated systems. Journal of Pharmaceutical Sciences, 2001, 90, 607-616.	3.3	33
182	Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug. Pharmaceutical Research, 2001, 18, 1006-1011.	3.5	75
183	Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. Pharmaceutical Research, 2001, 18, 311-315.	3.5	79
184	Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharmaceutical Research, 2001, 18, 1472-1475.	3.5	53
185	Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharmaceutical Research, 2001, 18, 1701-1708.	3.5	126
186	Optimizing iontophoretic drug delivery: identification and distribution of the charge-carrying species. Pharmaceutical Research, 2001, 18, 1709-1713.	3.5	41
187	Characterization of the iontophoretic permselectivity properties of human and pig skin. Journal of Controlled Release, 2001, 70, 213-217.	9.9	161
188	In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. Journal of Controlled Release, 2001, 71, 319-327.	9.9	108
189	Enhanced skin permeation of a lipophilic drug using supersaturated formulations. Journal of Controlled Release, 2001, 73, 245-253.	9.9	67
190	Piroxicam delivery into human stratum corneum in vivo: iontophoresis versus passive diffusion. Journal of Controlled Release, 2001, 76, 73-79.	9.9	48
191	Modeling transdermal drug release. Advanced Drug Delivery Reviews, 2001, 48, 159-172.	13.7	214
192	Permeation enhancement of a highly lipophilic drug using supersaturated systems. Journal of Pharmaceutical Sciences, 2001, 90, 605.	3.3	3
193	Transdermal drug delivery: overcoming the skin's barrier function. Pharmaceutical Science & Technology Today, 2000, 3, 318-326.	0.7	523
194	Iontophoresis: electrorepulsion and electroosmosis. Journal of Controlled Release, 2000, 64, 129-132.	9.9	270
195	Does epidermal turnover reduce percutaneous penetration?. Pharmaceutical Research, 2000, 17, 1414-1419.	3.5	55
196	Normalization of stratum corneum barrier function and transepidermal water loss in vivo. Pharmaceutical Research, 2000, 17, 1148-1150.	3.5	106
197	Recovery of human skin impedance in vivo after lontophoresis: Effect of metal ions. AAPS PharmSci, 2000, 2, 38-44.	1.3	9
198	The determination of a diffusional pathlength through the stratum corneum. International Journal of Pharmaceutics, 1999, 188, 121-124.	5.2	18

#	Article	IF	CITATIONS
199	Chemical uptake into human stratum corneum in vivo from volatile and non-volatile solvents. Pharmaceutical Research, 1999, 16, 1288-1293.	3.5	73
200	Electrorepulsion versus electroosmosis: effect of pH on the iontophoretic flux of 5-fluorouracil. Pharmaceutical Research, 1999, 16, 758-761.	3.5	73
201	Noninvasive sampling of phenylalanine by reverse iontophoresis. Journal of Controlled Release, 1999, 61, 65-69.	9.9	54
202	Iontophoretic permselectivity of mammalian skin: characterization of hairless mouse and porcine membrane models. Pharmaceutical Research, 1998, 15, 984-987.	3.5	33
203	Stratum corneum thickness and apparent water diffusivity: facile and noninvasive quantitation in vivo. Pharmaceutical Research, 1998, 15, 492-494.	3.5	57
204	Ion mobility across human stratum corneum in vivo. Journal of Pharmaceutical Sciences, 1998, 87, 1508-1511.	3.3	17
205	Transdermal iontophoresis: modulation of electroosmosis by polypeptides. Journal of Controlled Release, 1998, 50, 283-289.	9.9	41
206	Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. Journal of Controlled Release, 1998, 51, 47-56.	9.9	77
207	Development of Skin Barrier Function in Premature Infants. Journal of Investigative Dermatology, 1998, 111, 320-326.	0.7	227
208	TRANSDERMAL DRUG DELIVERY. Dermatologic Clinics, 1998, 16, 289-299.	1.7	55
209	Visualization and Quantitation of Iontophoretic Pathways Using Confocal Microscopy. Journal of Investigative Dermatology Symposium Proceedings, 1998, 3, 136-142.	0.8	46
210	Characterization of the permeability barrier of human skin <i>in vivo</i> . Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1562-1567.	7.1	188
211	Transdermal and Skin-Targeted Drug Delivery. Journal of Cutaneous Medicine and Surgery, 1997, 2, 108-119.	1.2	2
212	Acute effects of iontophoresis on human skin in vivo: cutaneous blood flow and transepidermal water loss measurements. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 43, 133-138.	4.3	15
213	Delivery of a hydrophilic solute through the skin from novel microemulsion systems. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 43, 37-42.	4.3	161
214	lontophoretic Transport Pathways: Dependence on Penetrant Physicochemical Properties. Journal of Pharmaceutical Sciences, 1997, 86, 1385-1389.	3.3	52
215	Transdermal therapy and diagnosis by iontophoresis. Trends in Biotechnology, 1997, 15, 288-290.	9.3	59
216	Interaction between penetration enhancers and iontophoresis: effect on human skin impedance in vivo. Journal of Controlled Release, 1997, 44, 33-42.	9.9	45

#	Article	IF	CITATIONS
217	Iontophoresis of poly-L-lysines: the role of molecular weight?. Pharmaceutical Research, 1997, 14, 1322-1331.	3.5	48
218	lontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. , 1997, 14, 1258-1263.		70
219	The effect of current on skin barrier function in vivo: recovery kinetics post-iontophoresis. Pharmaceutical Research, 1997, 14, 1252-1257.	3.5	31
220	Reverse iontophoresis — Parameters determining electroosmotic flow: I. pH and ionic strength. Journal of Controlled Release, 1996, 38, 159-165.	9.9	59
221	Reverse iontophoresis — parameters determining electro-osmotic flow. II. Electrode chamber formulation. Journal of Controlled Release, 1996, 42, 29-36.	9.9	33
222	Iontophoresis of bases, nucleosides, and nucleotides. Pharmaceutical Research, 1996, 13, 553-558.	3.5	21
223	Stratum corneum lipids of human epidermal keratinocyte air-liquid cultures: implications for barrier function. Pharmaceutical Research, 1996, 13, 1162-1167.	3.5	27
224	Controlled Release Technologies: Current Status and Future Prospects. Pharmaceutical Research, 1996, 13, 1759-1759.	3.5	7
225	Current status and future prospects of transdermal drug delivery. Pharmaceutical Research, 1996, 13, 1765-1769.	3.5	204
226	Iontophoresis of nafarelin across human skin in vitro. Pharmaceutical Research, 1996, 13, 798-800.	3.5	20
227	The effect of iontophoresis on skin barrier integrity: non-invasive evaluation by impedance spectroscopy and transepidermal water loss. Pharmaceutical Research, 1996, 13, 957-960.	3.5	42
228	Transdermal delivery of peptides by iontophoresis. Nature Biotechnology, 1996, 14, 1710-1713.	17.5	62
229	Metabolic Approaches To Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors. Journal of Pharmaceutical Sciences, 1996, 85, 643-648.	3.3	74
230	Imaging Regions of Transport Across Human Stratum Corneum during High-Voltage and Low-Voltage Exposures. Journal of Pharmaceutical Sciences, 1996, 85, 1363-1370.	3.3	82
231	Methods for Assessing Percutaneous Absorption. ATLA Alternatives To Laboratory Animals, 1996, 24, 81-106.	1.0	145
232	Optimization ofin VitroFlux Through Hairless Mouse Skin of Cidofovir, a Potent Nucleotide Analog. Journal of Pharmaceutical Sciences, 1995, 84, 750-754.	3.3	13
233	A sweeter life for diabetics?. Nature Medicine, 1995, 1, 1132-1133.	30.7	18
234	Iontophoretic delivery of nafarelin across the skin. International Journal of Pharmaceutics, 1995, 117, 165-172.	5.2	49

#	Article	IF	CITATIONS
235	Effects of iontophoresis on the electrical properties of human skin in vivo. International Journal of Pharmaceutics, 1995, 124, 137-142.	5.2	31
236	Iontophoresis of nicotine in vitro: pulsatile drug delivery across the skin?. Journal of Controlled Release, 1995, 33, 285-292.	9.9	22
237	Iontophoresis of nafarelin: Effects of current density and concentration on electrotransport in vitro. Journal of Controlled Release, 1995, 35, 35-40.	9.9	40
238	Current profile regulates iontophoretic delivery of amino acids across the skin. Journal of Controlled Release, 1995, 37, 239-249.	9.9	24
239	Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. Journal of Controlled Release, 1995, 37, 299-306.	9.9	247
240	The electrical characteristics of human skin in vivo. Pharmaceutical Research, 1995, 12, 1605-1613.	3.5	77
241	A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharmaceutical Research, 1995, 12, 1628-1633.	3.5	270
242	Reverse iontophoresis: noninvasive glucose monitoring in vivo in humans. Pharmaceutical Research, 1995, 12, 1869-1873.	3.5	118
243	Characterization of Low-Temperature (i.e., <65° C) Lipid Transitions in Human Stratum Corneum. Journal of Investigative Dermatology, 1994, 103, 233-239.	0.7	155
244	What is the transport-limiting barrier in iontophoresis?. International Journal of Pharmaceutics, 1994, 101, R1-R5.	5.2	8
245	Characterization of convective solvent flow during iontophoresis. Pharmaceutical Research, 1994, 11, 929-935.	3.5	101
246	Workshop III Report: Scaleup of Liquid and Semisolid Disperse Systems. Pharmaceutical Research, 1994, 11, 1216-1220.	3.5	5
247	Penetration of industrial chemicals across the skin: A predictive model. American Journal of Industrial Medicine, 1993, 23, 711-719.	2.1	366
248	Effect of current, ionic strength and temperature on the electrical properties of skin. Journal of Controlled Release, 1993, 27, 115-125.	9.9	75
249	Reverse iontophoresis: development of a noninvasive approach for glucose monitoring. Pharmaceutical Research, 1993, 10, 1751-1755.	3.5	109
250	Convective solvent flow across the skin during iontophoresis. Pharmaceutical Research, 1993, 10, 1315-1320.	3.5	151
251	The influence of molecular volume and hydrogen-bonding on peptide transport across epithelial membranes. Pharmaceutical Research, 1993, 10, 635-637.	3.5	20
252	Validation of reflectance infrared spectroscopy as a quantitative method to measure percutaneous absorption in vivo. Pharmaceutical Research, 1993, 10, 1500-1506.	3.5	68

#	Article	IF	CITATIONS
253	Uptake of Two Zwitterionic Surfactants into Human Skin in Vivo. Toxicology and Applied Pharmacology, 1993, 120, 224-227.	2.8	9
254	Are Water Permeability Measurements Sufficient to Characterize in Vitro Cultured Human Skin Surrogates?. Cutaneous and Ocular Toxicology, 1993, 12, 139-159.	0.3	1
255	Metals and the Skin. Critical Reviews in Toxicology, 1993, 23, 171-235.	3.9	121
256	In vitro and in vivo iontophoresis of a tripeptide across nude rat skin. Journal of Controlled Release, 1992, 20, 209-217.	9.9	51
257	Routes of ionic permeability through mammalian skin. Solid State Ionics, 1992, 53-56, 165-169.	2.7	32
258	Visualization of iontophoretic pathways with confocal microscopy and the vibrating probe electrode. Solid State Ionics, 1992, 53-56, 197-206.	2.7	35
259	Sonophoresis. II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharmaceutical Research, 1992, 09, 1043-1047.	3.5	148
260	Sonophoresis. I. The use of high-frequency ultrasound to enhance transdermal drug delivery. Pharmaceutical Research, 1992, 09, 559-564.	3.5	120
261	Predicting skin permeability. Pharmaceutical Research, 1992, 09, 663-669.	3.5	1,247
262	Cutaneous metabolism of nitroglycerin in vitro. II. Effects of skin condition and penetration enhancement. Pharmaceutical Research, 1992, 09, 303-306.	3.5	24
263	Cutaneous metabolism of nitroglycerin in vitro. I. Homogenized versus intact skin. Pharmaceutical Research, 1992, 09, 187-190.	3.5	10
264	(D) Routes of delivery: Case studies. Advanced Drug Delivery Reviews, 1992, 8, 291-329.	13.7	88
265	Transdermal iontophoresis of amino acids and peptides in vitro. Journal of Controlled Release, 1992, 21, 187-190.	9.9	24
266	Iontophoretic delivery of piroxicam across the skin in vitro. Journal of Controlled Release, 1992, 22, 57-67.	9.9	31
267	Rate control in transdermal drug delivery?. International Journal of Pharmaceutics, 1992, 82, R1-R6.	5.2	65
268	Enhancement of propranolol hydrochloride and diazepam skin absorption in vitro. II: Drug, vehicle, and enhancer penetration kinetics. Journal of Pharmaceutical Sciences, 1992, 81, 330-333.	3.3	21
269	Structureâ€Permeability Relationships in Percutaneous Penetration. Journal of Pharmaceutical Sciences, 1992, 81, 603-604.	3.3	49
270	In vivo percutaneous penetration/absorption. International Journal of Pharmaceutics, 1991, 74, 1-8.	5.2	12

#	Article	IF	CITATIONS
271	The effects of zwitterionic surfactants on skin barrier function. Fundamental and Applied Toxicology, 1991, 16, 41-50.	1.8	22
272	Percutaneous penetration of para-substituted phenols in vitro. Fundamental and Applied Toxicology, 1991, 17, 575-583.	1.8	45
273	Lineweaver-Burk analysis of skin penetration enhancement. Journal of Controlled Release, 1991, 16, 263-266.	9.9	0
274	Examination of the effect of ethanol on human stratum corneum in vivo using infrared spectroscopy. Journal of Controlled Release, 1991, 16, 299-304.	9.9	162
275	Mechanism and enhancement of solute transport across the stratum corneum. Journal of Controlled Release, 1991, 15, 249-260.	9.9	86
276	Iontophoretic delivery of a series of tripeptides across the skin in vitro. Pharmaceutical Research, 1991, 08, 1121-1127.	3.5	89
277	Does hydration affect intercellular lipid organization in the stratum corneum?. Pharmaceutical Research, 1991, 08, 1064-1065.	3.5	65
278	Percutaneous penetration kinetics of nitroglycerin and its dinitrate metabolites across hairless mouse skin in vitro. Pharmaceutical Research, 1991, 08, 1231-1237.	3.5	8
279	Iontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharmaceutical Research, 1991, 08, 1113-1120.	3.5	108
280	Barrier Function of Human Keratinocyte Cultures Grown at the Air-Liquid Interface. Journal of Investigative Dermatology, 1991, 96, 323-327.	0.7	97
281	Sites of Iontophoretic Current Flow Into the Skin: Identification and Characterization with the Vibrating Probe Electrode. Journal of Investigative Dermatology, 1991, 97, 55-64.	0.7	112
282	Enhancement of Propranolol Hydrochloride and Diazepam Skin Absorption In Vitro: Effect of Enhancer Lipophilicity. Journal of Pharmaceutical Sciences, 1991, 80, 32-35.	3.3	100
283	Percutaneous Penetration of para-Substituted Phenols in Vitro. Toxicological Sciences, 1991, 17, 575-583.	3.1	1
284	The Effects of Zwitterionic Surfactants on Skin Barrier Function. Toxicological Sciences, 1991, 16, 41-50.	3.1	1
285	Strategies to Enhance Permeability via Stratum Corneum Lipid Pathways. Advances in Lipid Research, 1991, 24, 173-210.	1.8	34
286	Examination of Stratum Corneum Barrier Function In Vivo by Infrared Spectroscopy. Journal of Investigative Dermatology, 1990, 95, 403-408.	0.7	209
287	Cutaneous pharmacodynamics of transdermally delivered isosorbide dinitrate. Pharmaceutical Research, 1990, 07, 1298-1301.	3.5	2
288	Optimization of topical therapy: partitioning of drugs into stratum corneum. Pharmaceutical Research, 1990, 07, 1320-1324.	3.5	93

#	Article	IF	CITATIONS
289	Percutaneous penetration enhancement in vivo measured by attenuated total reflectance infrared spectroscopy. Pharmaceutical Research, 1990, 07, 835-841.	3.5	93
290	Partitioning of Chemicals into Human Stratum Corneum: Implications for Risk Assessment following Dermal Exposure. Toxicological Sciences, 1990, 15, 99-107.	3.1	2
291	The Relationship between pKa and Skin Irritation for a Series of Basic Penetrants in Man. Toxicological Sciences, 1990, 15, 760-766.	3.1	2
292	On the determination of drug release rates from topical dosage forms. International Journal of Pharmaceutics, 1990, 60, R1-R3.	5.2	37
293	Partitioning of chemicals into human stratum corneum: Implications for risk assessment following dermal exposure. Fundamental and Applied Toxicology, 1990, 15, 99-107.	1.8	43
294	In vivo percutaneous absorption of chemicals: A multiple dose study in rhesus monkeys. Food and Chemical Toxicology, 1990, 28, 129-132.	3.6	11
295	mechanism of percutaneous penetration enhancement: effect of n-alkanols on the permeability barrier of hairless mouse skin. Journal of Controlled Release, 1990, 12, 103-112.	9.9	85
296	Controlled drug release from a novel liposomal delivery system. II. Transdermal delivery characteristics. Journal of Controlled Release, 1990, 12, 25-30.	9.9	45
297	Oleic acid concentration and effect in human stratum corneum: non-invasive determination by attenuated total reflectance infrared spectroscopy in vivo. Journal of Controlled Release, 1990, 12, 67-75.	9.9	68
298	Skin Pharmacology and Dermatology. Developments in Cardiovascular Medicine, 1990, , 141-174.	0.1	13
299	Relationship of PKA and Acute Skin Irritation in Humans. Cutaneous and Ocular Toxicology, 1989, 8, 481-492.	0.3	4
300	Percutaneous Penetration and Mass Balance Accountability: Technique and Implications for Dermatology. Cutaneous and Ocular Toxicology, 1989, 8, 439-451.	0.3	10
301	Noninvasive sampling of biological fluids by iontophoresis. Pharmaceutical Research, 1989, 06, 988-990.	3.5	82
302	The effect of aging on percutaneous absorption in man. Journal of Pharmacokinetics and Pharmacodynamics, 1989, 17, 617-630.	0.6	141
303	Assessment of skin barrier function using transepidermal water loss: effect of age. Pharmaceutical Research, 1989, 06, 949-953.	3.5	106
304	Cutaneous responses to topical methyl nicotinate in black, oriental, and caucasian subjects. Archives of Dermatological Research, 1989, 281, 95-98.	1.9	56
305	In Vitro Percutaneous Penetration: Evaluation of the Utility of Hairless Mouse Skin. Journal of Investigative Dermatology, 1989, 93, 87-91.	0.7	26
306	Mass balance and dose accountability in percutaneous absorption studies: development of a nonocclusive application system. Pharmaceutical Research, 1988, 05, 313-315.	3.5	20

#	Article	IF	CITATIONS
307	A new system for in vitro studies of iontophoresis. Pharmaceutical Research, 1988, 05, 443-446.	3.5	102
308	Physicochemical aspects of percutaneous penetration and its enhancement. Pharmaceutical Research, 1988, 05, 753-758.	3.5	90
309	Bioavailability of Topically Administered Steroids: A "Mass Balance―Technique. Journal of Investigative Dermatology, 1988, 91, 29-33.	0.7	76
310	The relationship of pKa and acute skin irritation in man. Pharmaceutical Research, 1988, 05, 660-663.	3.5	32
311	Membrane models for skin penetration studies. Chemical Reviews, 1988, 88, 455-472.	47.7	68
312	Pharmacokinetic Considerations in the Use of Newer Transdermal Formulations. Clinical Pharmacokinetics, 1988, 15, 114-131.	3.5	27
313	Laser Doppler velocimetric measurements of skin blood flow: a reply. International Journal of Pharmaceutics, 1988, 45, 263-265.	5.2	4
314	In vitro and in vivo enhancement of skin permeation with oleic and lauric acids. International Journal of Pharmaceutics, 1988, 48, 103-111.	5.2	94
315	Percutaneous absorption of hydroquinone in humans: Effect of 1â€dodecylazacycloheptanâ€2â€one (azone) and the 2â€ethylhexyl ester of 4â€(dimethylamino)benzoic acid (escalol 507). Journal of Toxicology and Environmental Health - Part A: Current Issues, 1988, 24, 279-289.	2.3	23
316	Physicochemical Models for Percutaneous Absorption. ACS Symposium Series, 1987, , 84-97.	0.5	2
317	Transdermal drug delivery: A perspective. Journal of Controlled Release, 1987, 4, 237-251.	9.9	51
318	The effect of penetration enhancers on the kinetics of percutaneous absorption. Journal of Controlled Release, 1987, 5, 43-51.	9.9	33
319	Controlled drug release from a novel liposomal delivery system. I. Investigation of transdermal potential. Journal of Controlled Release, 1987, 5, 211-221.	9.9	46
320	Transdermal drug delivery and cutaneous metabolism. Xenobiotica, 1987, 17, 325-343.	1.1	95
321	Title is missing!. Pharmaceutical Research, 1987, 04, 265-267.	3.5	141
322	Interpretation and prediction of the kinetics of transdermal drug delivery: oestradiol, hyoscine and timolol. International Journal of Pharmaceutics, 1986, 32, 159-163.	5.2	32
323	Percutaneous Absorption in the Aged. Dermatologic Clinics, 1986, 4, 455-465.	1.7	44
324	Pharmacodynamic Measurement of Percutaneous Penetration Enhancement In Vivo. Journal of Pharmaceutical Sciences, 1986, 75, 374-377.	3.3	42

#	Article	IF	CITATIONS
325	Percutaneous Penetration of Nicotinates: In Vivo and In Vitro Measurements. Journal of Pharmaceutical Sciences, 1986, 75, 968-972.	3.3	42
326	Determination of vehicle effects on percutaneous absorption by laser Doppler velocimetry. Archives of Dermatological Research, 1986, 278, 500-502.	1.9	11
327	The bioavailability of dermatological and other topically administered drugs. Pharmaceutical Research, 1986, 03, 253-262.	3.5	26
328	The influence of urea on percutaneous absorption. Pharmaceutical Research, 1986, 03, 294-297.	3.5	42
329	Optical Techniques for Monitoring Cutaneous Microcirculation International Journal of Dermatology, 1985, 24, 88-94.	1.0	31
330	Percutaneous absorption in man: A kinetic approach. Toxicology and Applied Pharmacology, 1985, 78, 123-129.	2.8	66
331	Kinetic analysis of transdermal nitroglycerin delivery. Pharmaceutical Research, 1985, 02, 206-211.	3.5	22
332	Pharmacokinetic Interpretation of the Plasma Levels of Clonidine Following Transdermal Delivery. Journal of Pharmaceutical Sciences, 1985, 74, 1016-1018.	3.3	37
333	Percutaneous Absorption of Steroids: Effect of Repeated Application. Journal of Pharmaceutical Sciences, 1985, 74, 1337-1339.	3.3	34
334	The microbial degradation of topically applied drugs. International Journal of Pharmaceutics, 1985, 26, 89-97.	5.2	24
335	Transdermal drug delivery to neonates. International Journal of Pharmaceutics, 1985, 24, 259-265.	5.2	7
336	Transdermal drug delivery: a simplified pharmacokinetic approach. International Journal of Pharmaceutics, 1985, 24, 267-274.	5.2	39
337	Are there age and racial differences to methyl nicotinate—induced vasodilatation in human skin?. Journal of the American Academy of Dermatology, 1985, 12, 1001-1006.	1.2	81
338	Percutaneous Absorption: Interpretation of In Vitro Data and Risk Assessment. ACS Symposium Series, 1985, , 3-17.	0.5	5
339	Transdermal Absorption Kinetics. ACS Symposium Series, 1985, , 19-31.	0.5	4
340	The prediction of plasma levels of drugs following transdermal application. Journal of Controlled Release, 1985, 1, 177-182.	9.9	35
341	Optical Techniques for Monitoring Cutaneous Microcirculation. International Journal of Dermatology, 1985, 24, 88-94.	1.0	1
342	Pharmacodynamic measurements of methyl nicotinate percutaneous absorption. Pharmaceutical Research, 1984, 01, 76-81.	3.5	45

#	Article	IF	CITATIONS
343	Correction factors for determining body exposure from forearm percutaneous absorption data. Journal of Applied Toxicology, 1984, 4, 26-28.	2.8	32
344	Prediction of Drug Disposition Kinetics in Skin and Plasma Following Topical Administration. Journal of Pharmaceutical Sciences, 1984, 73, 883-887.	3.3	37
345	A theoretical description of the effects of volatility and substantivity on percutaneous absorption. International Journal of Pharmaceutics, 1984, 18, 139-147.	5.2	9
346	Solute transport resistance at the octanol-water interface. International Journal of Pharmaceutics, 1984, 19, 129-137.	5.2	21
347	Pharmacokinetics of percutaneous absorption with concurrent metabolism. International Journal of Pharmaceutics, 1984, 20, 43-51.	5.2	28
348	Solute transport and perturbation at liquid/liquid interfaces. Faraday Discussions of the Chemical Society, 1984, 77, 127.	2.2	9
349	Noninvasive Assessment of Local Nicotinate Pharmacodynamics by Photoplethysmography. Journal of Investigative Dermatology, 1983, 80, 499-503.	0.7	29
350	Physicochemical interpretation of the pharmacokinetics of percutaneous absorption. Journal of Pharmacokinetics and Pharmacodynamics, 1983, 11, 189-203.	0.6	47
351	Malathion percutaneous absorption after repeated administration to man. Toxicology and Applied Pharmacology, 1983, 68, 116-119.	2.8	49
352	Interfacial transfer kinetics of 22Na+ across a synthetic phospholipid—protein membrane. Journal of Colloid and Interface Science, 1983, 94, 54-59.	9.4	2
353	Kinetics and Thermodynamics of Interfacial Transfer. Journal of Pharmaceutical Sciences, 1983, 72, 142-145.	3.3	15
354	Noninvasive Assessments of the Percutaneous Absorption of Methyl Nicotinate in Humans. Journal of Pharmaceutical Sciences, 1983, 72, 1077-1079.	3.3	58
355	Drug Delivery to Local Subcutaneous Structures Following Topical Administration. Journal of Pharmaceutical Sciences, 1983, 72, 1375-1380.	3.3	47
356	Percutaneous absorption: transport in the dermis. International Journal of Pharmaceutics, 1983, 15, 125-148.	5.2	23
357	Percutaneous absorption: multidose pharmacokinetics. International Journal of Pharmaceutics, 1983, 17, 23-28.	5.2	10
358	SOLUTE TRANSFER ACROSS LIQUID-LIQUID INTERFACES. Annals of the New York Academy of Sciences, 1983, 404, 194-197.	3.8	0
359	Solute transfer across liquid-liquid interfaces. Kinetic and thermodynamic evaluation. The Journal of Physical Chemistry, 1982, 86, 2861-2866.	2.9	9
360	Kinetics of solute transfer across aqueous phase-liquid hydrocarbon interfaces. The Journal of Physical Chemistry, 1982, 86, 280-283.	2.9	13

#	Article	IF	CITATIONS
361	Percutaneous metabolism with saturable enzyme kinetics. International Journal of Pharmaceutics, 1982, 11, 187-197.	5.2	39
362	Calculations of drug release rates from particles. International Journal of Pharmaceutics, 1982, 11, 199-207.	5.2	52
363	A pharmacokinetic model for percutaneous absorption. International Journal of Pharmaceutics, 1982, 11, 119-129.	5.2	101
364	The influence of urea on the kinetics of interfacial transfer. Journal of Colloid and Interface Science, 1982, 87, 107-114.	9.4	6
365	Rapid radial transport of methyl nicotinate in the dermis. Archives of Dermatological Research, 1982, 273, 91-95.	1.9	20
366	Calculations of drug release rates from cylinders. International Journal of Pharmaceutics, 1981, 8, 159-165.	5.2	6
367	Transport across a phospholipid barrier. Journal of Colloid and Interface Science, 1981, 83, 130-137.	9.4	13
368	Capillary diffusion and interfacial kinetics. Journal of Colloid and Interface Science, 1981, 80, 386-392.	9.4	1
369	Interfacial transport of salicylic acid. Journal of Colloid and Interface Science, 1981, 81, 69-74.	9.4	16
370	A theoretical description relating skin penetration to the thickness of the applied medicament. International Journal of Pharmaceutics, 1980, 6, 321-332.	5.2	61
371	Long-time solution of the equations describing the flow of 22Na+ in a finite composite system containing a synthetic phospholipid-protein membrane: Calculation of permeability coefficient. International Journal of Pharmaceutics, 1980, 4, 241-248.	5.2	2
372	A novel method to study the permeability of a phospholipid barrier. Journal of the Chemical Society Chemical Communications, 1979, , 729.	2.0	6
373	The estimation of diffusion coefficients using the rotating diffusion cell. International Journal of Pharmaceutics, 1979, 3, 143-149.	5.2	18
374	Biological Models to Study Skin Permeation. , 0, , 155-172.		13
375	Correction to "Skin Pharmacokinetics of Transdermal Scopolamine: Measurements and Modeling― Molecular Pharmaceutics, 0, , .	4.6	0